Theravance Biopharma Inc (0TB) — Long-term Investment Intensity
Theravance Biopharma Inc (0TB) has a Long-term Investment Intensity of 0.7% as of September 2025. Long-term investments of €3.03 Million represent 0.7% of total assets of €415.46 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check 0TB total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Theravance Biopharma Inc Long-term Investment Intensity (2014–2021)
This chart shows how Theravance Biopharma Inc's Long-term Investment Intensity has evolved across 8 annual periods from 2014 to 2021. As of September 2025, the intensity stands at 0.7%, reflecting long-term investments of €3.03 Million against total assets of €415.46 Million EUR. Explore 0TB debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Theravance Biopharma Inc (2014–2021)
The table below presents the year-by-year Long-term Investment Intensity for Theravance Biopharma Inc from 2014 to 2021, covering 8 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see how much is Theravance Biopharma Inc worth.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2021 | 18.0% | €67.54 Million | €374.82 Million | ▲ +15.3 pp |
| 2020 | 2.7% | €12.75 Million | €469.06 Million | ▲ +1.5 pp |
| 2019 | 1.2% | €4.99 Million | €408.83 Million | ▼ -0.9 pp |
| 2018 | 2.1% | €11.87 Million | €560.24 Million | ▼ -7.3 pp |
| 2017 | 9.4% | €41.59 Million | €441.40 Million | ▼ -6.2 pp |
| 2016 | 15.6% | €99.56 Million | €639.25 Million | ▼ -1.4 pp |
| 2015 | 16.9% | €50.86 Million | €300.12 Million | ▲ +1.7 pp |
| 2014 | 15.2% | €51.40 Million | €337.77 Million | — |